Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.40 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MDM4 | O15151 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19668361 | 1.00 | FABP5 (0.40) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL1905118 | 0.92 | FABP5 (0.44) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL31210304 | 0.88 | PTGIR (0.41) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL19668362 | 0.88 | PTGIR (0.41) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL30416398 | 0.88 | PTGIR (0.41) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL599391 | 0.88 | PTGIR (0.41) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL5494109 | 0.86 | FABP5 (0.43) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL18301508 | 0.85 | FABP5 (0.39) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL29713658 | 0.84 | CHRNB2 (0.40) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL28916981 | 0.84 | CHRNB2 (0.40) | FABP5FABP7KMT2AMDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-05-22 | — | — | US | disclosed |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-12 | — | — | US | disclosed |
| CN-118165073-B | FAP inhibitor and preparation method and application thereof | 中国药科大学 | 2024-07-19 | — | — | CN | disclosed |
| CN-118165073-A | FAP inhibitor and preparation method and application thereof | 中国药科大学 | 2024-06-11 | — | — | CN | disclosed |
| US-10683334-B2 | Aqueously soluble and chemically stable glucagon peptides | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190218268-A1 | AQUEOUSLY SOLUBLE & CHEMICALLY STABLE GLUCAGON PEPTIDES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2019-07-18 | — | — | US | disclosed |
| EP-3463415-A1 | AQUEOUSLY SOLUBLE & CHEMICALLY STABLE GLUCAGON PEPTIDES | Indiana University Research & Technology Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3434259-A1 | AMINO ACID LIPIDS AND USES THEREOF | Marina Biotech, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-1599480-A1 | SUBSTITUTED HEXAHYDROPYRAZINO(1,2-A)PYRIMIDIN-4,7-DION DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-20050085483-A1 | Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-21 | — | — | US | disclosed |
| US-6858577-B1 | Indole peptidomimetics as thrombin receptor antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20050004131-A1 | Substituted hexahydropyrazino (1,2-a) pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-06 | — | — | US | disclosed |
| WO-2004072076-A1 | SUBSTITUTED HEXAHYDROPYRAZINO(1,2-A)PYRIMIDIN-4,7-DION DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
| US-20040014676-A1 | SRC kinase inhibitors useful for treating osteoporosis | ARIAD PHARMACEUTICALS INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030224999-A1 | Novel indole peptidomimetics as thrombin receptor antagonists | ZHANG HAN-CHENG (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030199455-A1 | Novel indazole peptidomimetics as thrombin receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2001000656-A2 | NOVEL INDAZOLE PEPTIDOMIMETICS AS THROMBIN RECEPTOR ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000657-A2 | NOVEL INDOLE PEPTIDOMIMETICS AS THROMBIN RECEPTOR ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | FABP5 2427/4885FABP7 2559/4885KMT2A 2735/4885 |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | FABP5 2537/4885FABP7 2103/4885KMT2A 1052/4885 |
| US-20190218268-A1 | AQUEOUSLY SOLUBLE & CHEMICALLY STABLE GLUCAGON PEPTIDES | IAPP, GLP1R, GCG | FABP5 1349/4885FABP7 654/4885KMT2A 3816/4885 |
| US-20040014676-A1 | SRC kinase inhibitors useful for treating osteoporosis | SRC, CTTN, YES1 | FABP5 2465/4885FABP7 4354/4885KMT2A 1865/4885 |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | FABP5 2253/4885FABP7 2379/4885KMT2A 2325/4885 |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | FABP5 2171/4885FABP7 2391/4885KMT2A 2293/4885 |
| US-20050085483-A1 | Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | DPYD, NUDT1, NT5C2 | FABP5 3411/4885FABP7 3771/4885KMT2A 4297/4885 |
| US-20030224999-A1 | Novel indole peptidomimetics as thrombin receptor antagonists | PTAFR, F2R, F2RL1 | FABP5 2269/4885FABP7 1840/4885KMT2A 3052/4885 |
| US-20050004131-A1 | Substituted hexahydropyrazino (1,2-a) pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | DPYD, TYMP, G6PD | FABP5 2669/4885FABP7 3570/4885KMT2A 4317/4885 |
| US-10683334-B2 | Aqueously soluble and chemically stable glucagon peptides | IAPP, GLP1R, GCG | FABP5 1228/4885FABP7 523/4885KMT2A 4206/4885 |
| US-20030199455-A1 | Novel indazole peptidomimetics as thrombin receptor antagonists | PTAFR, F2R, F2RL1 | FABP5 2463/4885FABP7 2635/4885KMT2A 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.